Research programme: acylfulvene analogues - MGI PharmaAlternative Names: MGI 4184
Latest Information Update: 16 Oct 2007
At a glance
- Originator University of California System
- Developer MGI Pharma
- Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jul 2006 This programme is still in active development
- 05 Dec 2003 Preclinical trials in Cancer in USA (unspecified route)